| Afamelanotide for Erythropoietic Protoporphyria.N Engl J Med | Random groups | 2015 |
| Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.JAMA Dermatol | Random groups | 2015 |
| Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.Arch Dermatol | Random groups | 2004 |
| Skin pigmentation and pharmacokinetics of melanotan-I in humans.Biopharm Drug Dispos | Random groups | 1997 |
| A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.BMC Neurol | No random groups | 2023 |
| Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.Skin Pharmacol Physiol | No random groups | 2015 |
| Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease.Clin Exp Dermatol | No random groups | 2014 |
| Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.J Eur Acad Dermatol Venereol | No random groups | 2014 |
| Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.Br J Dermatol | No random groups | 2011 |
| Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.Photochem Photobiol | No random groups | 2009 |
| Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.Photochem Photobiol | No random groups | 2000 |
| German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).Photodermatol Photoimmunol Photomed | Group followed over time | 2025 |
| The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.Br J Dermatol | Group followed over time | 2024 |
| Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.Orphanet J Rare Dis | Group followed over time | 2020 |
| A glimpse into the underground market of melanotan.Dermatol Online J | Group followed over time | 2018 |
| Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.Br J Dermatol | Group followed over time | 2015 |
| Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.Reports (MDPI) | Case reports | 2026 |
| From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.JAAD Case Rep | Case reports | 2026 |
| Erythropoietic protoporphyria in childhood: clinical clues, missed diagnoses and emerging therapy.Eur J Pediatr | Case reports | 2025 |
| Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.Hematology Am Soc Hematol Educ Program | Case reports | 2020 |
| The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.JAMA Dermatol | Case reports | 2013 |
| Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.Clin Toxicol (Phila) | Case reports | 2012 |
| A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023.Cureus | Review of studies | 2026 |
| New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin.Expert Opin Pharmacother | Review of studies | 2026 |
| Insights into Tanning Biology and Tanning Products.J Clin Aesthet Dermatol | Review of studies | 2026 |
| [Hormones and skin pigmentation: fundamentals and clinical relevance].Dermatologie (Heidelb) | Review of studies | 2026 |
| Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.Diseases | Review of studies | 2025 |
| Treatment Advances in Vitiligo: An Updated Review.Dermatol Pract Concept | Review of studies | 2025 |
| Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management.Liver Int | Review of studies | 2025 |
| Afamelanotide in protoporphyria and other skin diseases: a review.Postepy Dermatol Alergol | Review of studies | 2024 |
| A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.Skin Res Technol | Review of studies | 2024 |
| Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review.Dermatology | Review of studies | 2024 |
| Vitiligo: Pathogenesis and New and Emerging Treatments.Int J Mol Sci | Review of studies | 2023 |
| Targeting the central melanocortin system for the treatment of metabolic disorders.Nat Rev Endocrinol | Review of studies | 2023 |
| Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.Int J Mol Sci | Review of studies | 2023 |
| Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.Int J Mol Sci | Review of studies | 2023 |
| Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review.Biomed Pharmacother | Review of studies | 2023 |
| Immunopathogenesis and management of polymorphic light eruption.Dermatol Ther | Review of studies | 2021 |
| Porphyrias in the Age of Targeted Therapies.Diagnostics (Basel) | Review of studies | 2021 |
| Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.J Drugs Dermatol | Review of studies | 2021 |
| Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.Expert Rev Clin Pharmacol | Review of studies | 2021 |
| [Melanocortin peptides : Fundamentals, translational research, clinical dermatology, and future perspectives].Hautarzt | Review of studies | 2020 |
| 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel) | Review of studies | 2020 |
| Emerging drugs for the treatment of vitiligo.Expert Opin Emerg Drugs | Review of studies | 2020 |
| Phototherapy for Vitiligo.Dermatol Clin | Review of studies | 2020 |
| Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.Mol Genet Metab | Review of studies | 2019 |
| From pathogenesis of acne vulgaris to anti-acne agents.Arch Dermatol Res | Review of studies | 2019 |
| [Porphyrias-what is verified?].Internist (Berl) | Review of studies | 2018 |
| An overview of the cutaneous porphyrias.F1000Res | Review of studies | 2017 |
| Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.Int J Dermatol | Review of studies | 2017 |
| The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review.Health Soc Care Community | Review of studies | 2017 |
| Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.Clin Pharmacokinet | Review of studies | 2017 |
| Current and emerging treatments for vitiligo.J Am Acad Dermatol | Review of studies | 2017 |
| Interventional treatments for Hailey-Hailey disease.J Am Acad Dermatol | Review of studies | 2017 |
| Advances in the management of erythropoietic protoporphyria - role of afamelanotide.Appl Clin Genet | Review of studies | 2016 |
| Afamelanotide: A Review in Erythropoietic Protoporphyria.Am J Clin Dermatol | Review of studies | 2016 |
| [Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities].Hautarzt | Review of studies | 2016 |
| [Undesirable pigmentation].Hautarzt | Review of studies | 2015 |
| Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.Expert Rev Clin Pharmacol | Review of studies | 2015 |
| Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.Expert Opin Investig Drugs | Review of studies | 2014 |
| A review and update on melanocyte stimulating hormone therapy: afamelanotide.J Drugs Dermatol | Review of studies | 2013 |
| Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.Expert Opin Investig Drugs | Review of studies | 2010 |
| Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?Br J Dermatol | Review of studies | 2010 |
| Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.Peptides | Review of studies | 2006 |
| Discovery and development of novel melanogenic drugs. Melanotan-I and -II.Pharm Biotechnol | Review of studies | 1998 |
| A gel-forming α-MSH analog promotes lasting melanogenesis.Eur J Pharmacol | In animals | 2023 |
| Effects of the central melanocortin system on feed intake, metabolic hormones and insulin action in the sheep.J Anim Sci | In animals | 2023 |
| Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.Pharm Res | In animals | 2000 |
| Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.J Pharm Sci | In animals | 1996 |
| Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.Photochem Photobiol Sci | Other paper | 2026 |
| Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery.J Control Release | Other paper | 2026 |
| Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.J Pharm Biomed Anal | Other paper | 2026 |
| Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.J Dtsch Dermatol Ges | Other paper | 2026 |
| New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.Orphanet J Rare Dis | Other paper | 2025 |
| Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis.J Manag Care Spec Pharm | Other paper | 2025 |
| Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.Clin Exp Dermatol | Other paper | 2025 |
| Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS).J Pept Sci | Other paper | 2025 |
| A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre.Skin Health Dis | Other paper | 2025 |
| The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria.J Clin Endocrinol Metab | Other paper | 2025 |
| Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist.J Med Chem | Other paper | 2024 |
| Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation.ACS Appl Bio Mater | Other paper | 2024 |
| Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).ACS Pharmacol Transl Sci | Other paper | 2024 |
| When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion.Dermatol Reports | Other paper | 2024 |
| Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.Life (Basel) | Other paper | 2024 |
| Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England.Int J Environ Res Public Health | Other paper | 2024 |
| Erythropoietic protoporphyria and afamelanotide: a patient's perspective.Clin Exp Dermatol | Other paper | 2024 |
| Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.J Drugs Dermatol | Other paper | 2023 |
| Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria.Life (Basel) | Other paper | 2023 |
| Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide.J Dermatol | Other paper | 2023 |
| Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study.J Am Acad Dermatol | Other paper | 2023 |
| Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene mecA in Methicillin-Resistant Staphylococcus aureus (MRSA) Strains.BioTech (Basel) | Other paper | 2023 |
| Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study.Int J Environ Res Public Health | Other paper | 2023 |
| Implementation of a high-impact medication therapy subcommittee within a large academic medical center.Am J Health Syst Pharm | Other paper | 2023 |
| Discovery of novel N-(1-benzyl-1H-imidazol-2-yl)amide derivatives as melanocortin 1 receptor agonists.Bioorg Med Chem Lett | Other paper | 2022 |
| Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study.Mol Genet Metab | Other paper | 2022 |
| Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.Ther Adv Rare Dis | Other paper | 2021 |
| Structural insights into ligand recognition and activation of the melanocortin-4 receptor.Cell Res | Other paper | 2021 |
| Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor.Cell Res | Other paper | 2021 |
| Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.Genet Med | Other paper | 2021 |
| Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.Photochem Photobiol Sci | Other paper | 2021 |
| Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.JAMA Dermatol | Other paper | 2020 |
| [Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].Ned Tijdschr Tandheelkd | Other paper | 2020 |
| Afamelanotide in the Treatment of Dermatologic Disease.Skin Therapy Lett | Other paper | 2018 |
| Current challenges in photoprotection.J Am Acad Dermatol | Other paper | 2017 |
| Photoprotection: part I. Photoprotection by naturally occurring, physical, and systemic agents.J Am Acad Dermatol | Other paper | 2013 |
| A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.J Pharm Biomed Anal | Other paper | 2013 |
| Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal.Health Qual Life Outcomes | Other paper | 2010 |
| Nonsurgical innovations in the treatment of nonmelanoma skin cancer.J Clin Aesthet Dermatol | Other paper | 2010 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2009 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2007 |
| High-performance liquid chromatographic assay for Melanotan-1 ([Nle4-DPhe7]alpha-melanocyte-stimulating hormone) in biological matrices.J Chromatogr B Biomed Appl | Other paper | 1995 |